XKRX950220
Market cap15mUSD
Dec 20, Last price
1,112.00KRW
1D
-1.24%
1Q
-33.21%
IPO
-92.09%
Name
Neoimmunetech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-53.40b
L-11.59%
CFO
-49.76b
L+17.35%
Profile
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 29,548,150 | 36,985,699 | 70,116,733 | ||
Unusual Expense (Income) | |||||
NOPBT | (29,548,150) | (36,985,699) | (70,116,733) | ||
NOPBT Margin | |||||
Operating Taxes | 101,299 | 116,414 | 69,467 | ||
Tax Rate | |||||
NOPAT | (29,649,449) | (37,102,113) | (70,186,200) | ||
Net income | (53,404,510) -11.59% | (60,405,625) 15.10% | (52,482,337) 72.32% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 41,261 | 402,555 | 115,762,673 | ||
BB yield | -0.02% | -0.51% | -58.78% | ||
| Debt | |||||
Debt current | 1,352,622 | 1,279,295 | 1,283,799 | ||
Long-term debt | 6,463,214 | 8,423,599 | 10,305,423 | ||
Deferred revenue | |||||
Other long-term liabilities | 213,934 | 206,766 | 63,091 | ||
Net debt | (63,450,439) | (107,543,230) | (143,797,765) | ||
| Cash flow | |||||
Cash from operating activities | (49,760,750) | (42,404,803) | (33,886,577) | ||
CAPEX | (791) | (2,476,539) | (2,709,879) | ||
Cash from investing activities | 2,087 | (3,150,258) | (3,828,409) | ||
Cash from financing activities | (1,136) | (633,323) | 115,048,940 | ||
FCF | (28,001,021) | (37,443,341) | (74,222,653) | ||
| Balance | |||||
Cash | 69,072,408 | 117,075,102 | 154,470,573 | ||
Long term investments | 2,193,867 | 171,022 | 916,414 | ||
Excess cash | 71,266,275 | 117,246,124 | 155,386,987 | ||
Stockholders' equity | (246,514,445) | (170,955,181) | (109,239,527) | ||
Invested Capital | 325,492,669 | 295,610,160 | 277,080,326 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 98,849 | 19,728 | 19,029 | ||
Price | 2,025.00 -49.31% | 3,995.00 -61.40% | 10,350.00 | ||
Market cap | 200,170,217 153.99% | 78,811,390 -59.98% | 196,951,485 | ||
EV | 136,719,778 | (28,731,840) | 53,153,720 | ||
EBITDA | (26,338,569) | (34,183,617) | (68,243,575) | ||
EV/EBITDA | 0.84 | ||||
Interest | 225,280 | 261,390 | 219,153 | ||
Interest/NOPBT | |||||